The Adipoa programme, launched six months ago under the direction of Prof. Christian Jorgensen (Inserm) in Montpellier regional university hospital and Wurzburg university in Germany, offers hope for the 7 million patients suffering today from arthritis, the most frequent rheumatic disease. This programme, involving eighteen patients and unique in Europe, "uses cell therapy, i.e. adult progenitor stem cells harvested from the fatty tissues of the patient." They "are isolated after a treatment by collagenase injections, then multiplied and checked before being injected into the diseased joint in order to activate the regeneration of the cartilage."
Stem cells: a therapeutic response to arthritis?
Publié le : 5 April 2013
According to Prof. Jorgensen, "the first objective of the trial is to define the optimal dose of stem cells and to verify the absence of an inflammatory reaction and secondary effects […]. And we are finding a good tolerance level. Of course, we are also looking at the benefits regarding the development of the disease and we have seen an improvement in some patients."
In 2014, in France, a second research phase will be launched with 86 patients. Its goal is "to compare over one year the effectiveness of cell therapy with conventional treatments." By 2016, "the teams hope to be able to make this therapy accessible to a greater number of patients."